CME Group Stock Forecast, Price & News

CME Group (NASDAQ:CME) Frequently Asked Questions

Is CME Group a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CME Group stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.
View analyst ratings for CME Group or view top-rated stocks.

How has CME Group's stock been impacted by COVID-19?

CME Group's stock was trading at $194.6750 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CME stock has increased by 16.4% and is now trading at $226.55.
View which stocks have been most impacted by COVID-19.

When is CME Group's next earnings date?

CME Group is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for CME Group.

How were CME Group's earnings last quarter?

CME Group Inc. (NASDAQ:CME) released its quarterly earnings data on Wednesday, October, 27th. The financial services provider reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.55 by $0.05. The financial services provider had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.15 billion. CME Group had a trailing twelve-month return on equity of 8.60% and a net margin of 52.47%. The business's revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.38 EPS.
View CME Group's earnings history.

How often does CME Group pay dividends? What is the dividend yield for CME Group?

CME Group declared a quarterly dividend on Thursday, November 4th. Stockholders of record on Friday, December 10th will be given a dividend of $0.90 per share on Tuesday, December 28th. This represents a $3.60 annualized dividend and a yield of 1.59%. The ex-dividend date is Thursday, December 9th.
View CME Group's dividend history.

Is CME Group a good dividend stock?

CME Group pays an annual dividend of $3.60 per share and currently has a dividend yield of 1.64%. CME Group has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of CME Group is 53.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CME Group will have a dividend payout ratio of 50.21% next year. This indicates that CME Group will be able to sustain or increase its dividend.
View CME Group's dividend history.

What price target have analysts set for CME?

15 equities research analysts have issued 12-month target prices for CME Group's shares. Their forecasts range from $196.00 to $235.00. On average, they expect CME Group's share price to reach $218.08 in the next twelve months. This suggests that the stock has a possible downside of 3.7%.
View analysts' price targets for CME Group or view top-rated stocks among Wall Street analysts.

Who are CME Group's key executives?

CME Group's management team includes the following people:

• Terrence A. Duffy, Executive Chairman & Chief Executive Officer
• Julie Holzrichter, Chief Operating Officer & Senior Managing Director (LinkedIn Profile)
• John William Pietrowicz, Chief Financial Officer & Senior Managing Director
• Kevin Dean Kometer, Chief Information Officer & Senior MD
• Kendal Vroman, Chief Transformation Officer (LinkedIn Profile)

What is Terry Duffy's approval rating as CME Group's CEO?

144 employees have rated CME Group CEO Terry Duffy on Glassdoor.com. Terry Duffy has an approval rating of 83% among CME Group's employees.

Who are some of CME Group's key competitors?

Some companies that are related to CME Group include Intercontinental Exchange (ICE), Moody's (MCO), MSCI (MSCI), Nasdaq (NDAQ), Interactive Brokers Group (IBKR), Cboe Global Markets (CBOE), MarketAxess (MKTX), Arrow Financial (AROW), Marlin Business Services (MRLN) and California First Leasing (CFNB).
View all of CME's competitors.

What other stocks do shareholders of CME Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CME Group investors own include NVIDIA (NVDA), Mastercard (MA), PayPal (PYPL), Walt Disney (DIS), Visa (V), Netflix (NFLX), Boeing (BA), Alibaba Group (BABA), Cisco Systems (CSCO) and Intel (INTC).

What is CME Group's stock symbol?

CME Group trades on the NASDAQ under the ticker symbol "CME."

Who are CME Group's major shareholders?

CME Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (9.36%), BlackRock Inc. (7.11%), Edgewood Management LLC (2.68%), Capital Research Global Investors (2.37%), Parnassus Investments LLC (1.97%) and Parnassus Investments LLC (1.96%). Company insiders that own CME Group stock include Bryan T Durkin, Charles P Carey, Daniel R Glickman, Dennis Suskind, Elizabeth A Cook, Hilda Harris Piell, Howard J Siegel, John W Pietrowicz, Julie Holzrichter, Julie Winkler, Kathleen M Cronin, Ken Vroman, Kevin Kometer, Martin J Gepsman, Martin J Gepsman, Sean Tully, Terrence A Duffy, Timothy S Bitsberger and William R Shepard.
View institutional ownership trends for CME Group.

Which major investors are selling CME Group stock?

CME stock was sold by a variety of institutional investors in the last quarter, including Mawer Investment Management Ltd., Wellington Management Group LLP, Sepio Capital LP, Capital Research Global Investors, Caisse DE Depot ET Placement DU Quebec, Capital World Investors, Alliancebernstein L.P., and DekaBank Deutsche Girozentrale. Company insiders that have sold CME Group company stock in the last year include Bryan T Durkin, Dennis Suskind, Elizabeth A Cook, Hilda Harris Piell, Howard J Siegel, Julie Holzrichter, Julie Winkler, Kathleen M Cronin, Ken Vroman, Kevin Kometer, Martin J Gepsman, Sean Tully, Terrence A Duffy, and Timothy S Bitsberger.
View insider buying and selling activity for CME Group or view top insider-selling stocks.

Which major investors are buying CME Group stock?

CME stock was bought by a variety of institutional investors in the last quarter, including Parnassus Investments LLC, Parnassus Investments LLC, BlackRock Inc., Arrowstreet Capital Limited Partnership, Healthcare of Ontario Pension Plan Trust Fund, Troy Asset Management Ltd, Renaissance Technologies LLC, and CI Investments Inc.. Company insiders that have bought CME Group stock in the last two years include Terrence A Duffy, and William R Shepard.
View insider buying and selling activity for CME Group or or view top insider-buying stocks.

How do I buy shares of CME Group?

Shares of CME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CME Group's stock price today?

One share of CME stock can currently be purchased for approximately $226.55.

How much money does CME Group make?

CME Group has a market capitalization of $81.42 billion and generates $4.88 billion in revenue each year. The financial services provider earns $2.11 billion in net income (profit) each year or $6.78 on an earnings per share basis.

How many employees does CME Group have?

CME Group employs 4,370 workers across the globe.

When was CME Group founded?

CME Group was founded in 1848.

What is CME Group's official website?

The official website for CME Group is www.cmegroup.com.

Where are CME Group's headquarters?

CME Group is headquartered at 20 SOUTH WACKER DRIVE, CHICAGO IL, 60606.

How can I contact CME Group?

CME Group's mailing address is 20 SOUTH WACKER DRIVE, CHICAGO IL, 60606. The financial services provider can be reached via phone at (312) 930-1000, via email at [email protected], or via fax at 312-466-4410.